Rabies vaccinations: Are abbreviated intradermal schedules the future?

Clinical Infectious Diseases

Volumn 56, Issue 3, 2013, Pages 414-419

  Wieten, R W ^a   Leenstra, T ^a,b   Van Thiel, P P A M ^a,b   Van Vugt, M ^a   Stijnis, C ^a,b   Goorhuis, A ^a   Grobusch, M P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Ministerie van Defensie   (Netherlands)

Author keywords

booster; intradermal; pre exposure prophylaxis; rabies; vaccination

Indexed keywords

RABIES VACCINE;

ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG ADMINISTRATION ROUTE; HUMAN; PRIORITY JOURNAL; RABIES; VACCINATION;

HUMANS; INJECTIONS, INTRADERMAL; RABIES; RABIES VACCINES; RABIES VIRUS; VACCINATION;

EID: 84872343863     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis853     Document Type: Article

References (27)

1. Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005; 83:360-8.
2. World Health Organization. Rabies vaccines: WHO position statement. Weekly epidemiological record. 2010; 85:309-20. Available at: http://www.who.int/wer. Accessed 9 June 2012.
3. Meslin FX. Rabies as a traveler's risk, especially in high-endemicity areas. J Trav Med 2005; 12:S30-40.
4. Altmann M, Parola P, Delmont J, Brouqui P, Gautret P. Knowledge, attitudes, and practices of French trevelers from Marseille regarding rabies risk and prevention. J Trav Med 2009; 16:107-11.
5. Nicholson KG, Turner GS, Aoki FY. Immunization with a human diploid cell strain of rabies virus vaccine: two-year results. J Infect Dis 137:783-8.
6. Aoki FY, Tyrrell DA, Hill LE. Immunogenicity and acceptability of a human diploid-cell culture rabies vaccine in volunteers. Lancet 1975; 1:660-2.
7. Anderson GR, Schnurrenberger PR, Masterson RA, Wentworth FH. Avian embryo rabies immunization I. Duck-embryo vaccine administered intradermally in man. Am J Hyg 1960; 71:158-67.
8. Kositprapa C, Limsuwun K, Wilde H, et al. Immune response to simulated postexposure rabies booster vaccinations in volunteers who received preexposure vaccinations. Clin Infect Dis 1997; 25:614-6.
9. Roukens AH, Vossen AC, van Dissel JT, Visser LG. Reduced dose preexposure primary and booster intradermal rabies vaccination with a purified chick embryo cell vaccine (PCECV) is immunogenic and safe in adults. Vaccine 2008; 26:3438-42.
10. Warrell MJ. Intradermal rabies vaccination: the evolution and future of pre- and post-exposure prophylaxis. Curr Top Microbiol Immunol 2012; 351:139-57.
11. Roumiantzeff M, Ajjan N, Vincent-Falquet JC. Experience with preexposure rabies vaccination. Rev Infect Dis 1988; 10:S751-7.
12. Turner GS, Nicholson KG, Tyrrell DA, Aoki FY. Evaluation of a human diploid cell strain rabies vaccine: final report of a three year study of pre-exposure immunization. J Hyg (Lond) 1982; 89:101-10.
13. Khawplod P, Wilde H, Benjavongkulchai M, Sriaroon C, Chomchey P. Immunogenicity study of abbreviated rabies preexposure vaccination schedules. J Travel Med 2007; 14:173-6.
14. Pengsaa K, Limkittikul K, Sabchareon A, et al. A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. Pediatr Infect Dis J 2009; 28:335-7.
15. Arai YT, Ogata T, Oya A. Studies on Japanese-produced chick embryo cell culture rabies vaccines. Am J Trop Med Hyg 1991; 44:131-4.
16. Kamoltham T, Thinyounyoung W, Khawplod P, et al. Immunogenicity of simulated PCECV postexposure booster doses 1, 3 and 5 years after 2-dose and 3 dose primary rabies vaccination in schoolchildren. Adv Prev Med 2011; 403201.
17. Kamoltham T, Thinyounyong W, Phongchamnaphai P, et al. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. J Pediatr 2007; 151:173-7.
18. Strady A, Andreoletti L, Baumard S, Servettaz A, Jaussaud R, Strady A. Immunogenecity and booster efficacy of pre-exposure rabies vaccination. Trans R Soc Trop Med Hyg 2009; 103:1159-64.
19. Khawplod P, Jaijaroensup W, Sawangvaree A, Prakongsri S, Wilde H. One clinic visit for pre-exposure rabies vaccination (a preliminary one year study). Vaccine 2012; 30:2918-20.
20. Yang Y, Zhang JG. An experimental study in the endurance of immunologic memory of intradermal micro-injection with rabies vaccine and boosting immune effect. J Epidemiol 1999; 9:209-15.
21. Warrell MJ, Riddell A, Yu LM, et al. A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods. PLoS Negl Trop Dis 2008; 2:e224
22. Tantawichien T, Benjavongkulchai M, Limsuwan K, et al. Antibody response after a four-site intradermal booster vaccination with cellculture rabies vaccine. Clin Infect Dis 1999; 28:1100-3.
23. Khawplod P, Benjavongkulchai M, Limusanno S, et al. Four-site intradermal postexposure boosters in previously rabies vaccinated subjects. J Trav Med 2002; 9:153-5.
24. ClinicalTrials.gov. Simplifying the rabies pre-exposure vaccination. Belgium: Institute of Tropical Medicine. Available at: http://clinical trials.gov/ct2/show/NCT01388985?term=rabies&rank=11. Accessed 20 August 2012.
25. Kuwert EK, Barsenbach C, Werner J, et al. Early/high and late/low responders among HDCS vaccines? In: Kuwert EK, Wiktor TJ, Koprowski H, eds. Cell culture rabies vaccines and their protective effect in man. Geneva: International Green Cross, 1981; 160-7.
26. Strady C, Jassaud R, Beguinot I, Lienard M, Strady A. Predictive factors for the neutralising antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy. Vaccine 2000; 18:2661-7.
27. Intradermal adapter. Technology solutions for global health. Available at: http://www.path.org/publications/files/TS-update-id-adapt.pdf. Accessed 21 June 2012.